 Kazia Therapeutics Ltd ASX:KZA FRA:NV9 NASDAQ:KZIA has entered into a worldwide exclusive licensing agreement as well as a master services agreement with Evotec SE FRA:EVT a leading European drug discovery and development company. The agreement was made for EVT801 a small molecule, first-in class oncology drug candidate, for which Kazia expects to launch a phase-I clinical trial in 2021. 